Friday 6 November 2026 Export CGON’s income statement to Excel — free account

CG Oncology, Inc.

CGON Healthcare Biotechnology

CG Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, up 254.7% from fiscal 2024.

Revenue: −3.72%
EPS: −12.3%
Free cash flow: −25.2%
Total debt: 0.00%

Quarter to September 2026, against a year earlier

76.08 11.28 +17.41%

Follow CGON

Alert me

Market cap: $5.7B
P/E: 0.0×
Fwd P/E: −19.5×
Dividend yield: —
F-score: 2/9
Altman Z: 49.04
Beneish M: n/a
Dividend safety: n/a

Overview

CG Oncology, Inc. (CGON) P/S ratio

Alert me on P/S ratio

As of 6 November 2026, CG Oncology, Inc. (CGON) trades at a P/S ratio of 1,097×. Over the past ten years it has ranged from 0.0× (March 2024) to 4,500× (September 2025); the current reading is higher than 29% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/CGON/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="CG Oncology, Inc. P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/CGON/metrics/ps-ratio">CG Oncology, Inc. (CGON) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	714×	(54.64%)
FY2024	1,574×	—
FY2023	0.0×	—
FY2022	0.0×	—

Period	P/S ratio	Change
Sep 2026	1,022×	1.54%
Jun 2026	1,006×	(9.89%)
Mar 2026	1,117×	56.41%
Dec 2025	714×	(48.79%)
9 more quarters	Free account

Against its own ten years

Low 0.0× High 4,500×

Ten-year median 1,543×

Current reading's percentile 29

Company	P/S ratio
BLTE Belite Bio, Inc. Sponsored ADR compare	n/m
MANE Veradermics Incorporated compare	n/m
IMVT Immunovant, Inc. compare	n/m
KOD Kodiak Sciences Inc. compare	n/m
PTCT PTC Therapeutics, Inc. compare	4.8×
MIRM Mirum Pharmaceuticals, Inc. compare	9.2×
LGND Ligand Pharmaceuticals Incorporated compare	23.6×
SRRK Scholar Rock Holding Corporation compare	126×
CGON CG Oncology, Inc.	919×
Biotechnology industry median	9.2×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

CG Oncology, Inc. (CGON) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on CGON

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on CGON

Stockrow Weekly